Evidence map›Paper›PMID 39796232›Full record

ReviewInternational journal of molecular sciences2025

LEAP2 in Physiology-A Narrative Review.

Oskar Sosinski, Ewa Pruszynska-Oszmalek, Natalia Leciejewska, Maciej Sassek, Pawel Antoni Kolodziejski

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Mechanistic insights into the liver-brain axis during chronic liver disease.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Oskar SosinskiDepartment of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.
Ewa Pruszynska-OszmalekDepartment of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.ORCID 0000-0002-7182-6905
Natalia LeciejewskaDepartment of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.ORCID 0000-0002-0081-7585
Maciej SassekDepartment of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.
Pawel Antoni KolodziejskiDepartment of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.ORCID 0000-0003-0715-0223

Funding

National Science Center Poland 2021/41/B/NZ5/00446
6 · The paper itself

Abstract

Liver Enriched Antimicrobial Peptide 2 (LEAP2) is a fascinating peptide that has gained significant attention since its discovery in 2003. Initially identified as an antimicrobial peptide, LEAP2 has more recently been found to play a key role in the regulation of energy metabolism. One of the most notable functions of LEAP2 is its interaction with the ghrelin hormone, which is known for stimulating hunger. LEAP2 acts as an inhibitor of ghrelin, thereby reducing food intake and influencing energy balance. The physiological roles of LEAP2 extend beyond appetite suppression. Studies have shown that LEAP2 has an impact on insulin secretion, suggesting its potential involvement in glucose metabolism and possibly insulin sensitivity, which is crucial in managing conditions like type 2 diabetes. Moreover, LEAP2 levels appear to fluctuate based on factors such as gender, developmental stage, and even interventions like bariatric surgery, which is known for its role in managing obesity and diabetes. Given these findings, LEAP2 shows potential as a therapeutic target, particularly for addressing obesity and metabolic diseases such as type 2 diabetes. Its ability to influence food intake and energy balance makes it a promising candidate for further research into therapies aimed at weight regulation and glycemic control. In the future, LEAP2 could become an important agent in the development of treatments aimed at curbing obesity and its associated metabolic disorders.

Indexed as

Diabetes Mellitus, Type 2Energy MetabolismGhrelinObesityAnimalsAntimicrobial Cationic PeptidesBlood ProteinsEatingHumansInsulinInsulin ResistanceAntimicrobial Cationic PeptidesBlood ProteinsGhrelinInsulinliver-expressed antimicrobial peptide 2, humanamphibiansavianfishGHSRLiver Enriched Antimicrobial Peptide 2 (LEAP2)mammalsmetabolismreptiles

Identifiers

PMID39796232
PMCPMC11722547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.